Follicular thyroid carcinoma (FTC) frequently harbors the PAX8/PPARc fusion gene (PPFP); however, its oncogenic role and mechanism(s) of action remain undefined. We investigated PPFP's effects on cell growth, apoptosis, cell-cell, and cell-matrix interactions in immortalized human thyroid cells (Nthy-ori 3-1) and NIH 3T3 cells. PPFP expression increased the growth of transient and stable Nthy-ori transfectants (Bthreefold by 72 h). There was an 8.4% increase of cells in the S þ G2/M phase, a 7.8% decrease in cells in the G0 þ G1 phase and a 66% decline in apoptosis at 72 h. Stable Nthy-ori PPFP transfectants grew in soft agar, and PPFP-transfected NIH 3T3 cells exhibited efficient focus formation, suggesting loss of anchorage-dependent growth and contact inhibition, respectively. Overexpression of PPARc in Nthy-ori cells did not recapitulate PPFP's growth effects. Treatment of Nthy-ori cells with an irreversible PPARc inhibitor mimicked the growthpromoting effects of PPFP and co-expression of PPFP and PPARc blocked PPARc transactivation activity. Our data provide functional evidence that PPFP acts as an oncoprotein, whose transforming properties depend in part on inhibition of PPARc. Our data suggest that PPFP contributes to malignant transformation during FTC oncogenesis by acting on several cellular pathways, at least some of which are normally regulated by PPARc.
Introduction
The molecular pathogenesis of thyroid carcinoma is incompletely understood, but may involve mutations of RAS, TP53, and B-RAF (Fagin et al., 1993; Santoro et al., 1995; Fagin, 2002) , genetic events common to other cancer types (Hanahan and Weinberg, 2000; Knudson, 2001) . Somatic rearrangements of the RET proto-oncogene have been identified in papillary thyroid carcinoma (PTC), and result in aberrant RET tyrosine kinase activity (Bongarzone et al., 1989; Santoro et al., 1995) . These thyroid tumor-specific rearrangements may represent early, initiating oncogenic events, are unique to PTC, and may cause the PTC morphotype in animal models (Jhiang et al., 1998) .
A second type of somatic genetic rearrangement occurs in follicular thyroid carcinoma (FTC). It involves a chromosome 3p25 and 2q13 translocation , creating a fusion gene, encompassing the promoter and proximal 5 0 coding sequence of the thyroid-specific transcription factor PAX8 gene and most of the coding sequence of the PPARg gene. The PAX8 promoter, which is active in thyroid follicular cells (Mascia et al., 2002) , appears to drive the expression of PAX8/PPARg (PPFP) . PPFP has been identified in a significant proportion of FTC, but in few follicular adenoma (FA), PTC, or Hu¨rthle cell carcinoma, suggesting that it may represent an early FTC-specific oncogene Marques et al., 2002; Nikiforova et al., 2002; French et al., 2003; Nikiforova et al., 2003) . The oncogenic function(s) and mechanism(s) of PPFP remain unknown. Theoretically, PPFP oncogenic effects could relate to constitutive overexpression of the fulllength PPARg domain, interference with wild-type PPARg function, alterations of PAX8 function, formation of novel fusion gene activities, or a combination of such events . To address these issues, we examined the effects of PPFP on cell growth, cellcycle progression, apoptosis, anchorage independent growth, and colony formation, using PPFP-and PPARg-transfected cell culture models.
Results
PPFP expression in Nthy-ori 3-1 cells increases growth, due to increased cell cycle transit and decreased apoptosis
We examined the effects of PPFP expression on cell growth and apoptosis in transiently-and permanentlytransfected Nthy-ori cells, derived by SV40 large T-antigen immortalization of normal human thyroid cells. These cells display low levels of anchorageindependent growth, without evidence of malignant transformation, and retain some morphologic and physiological characteristics of normal human thyrocytes (Burns et al., 1989; Lemoine et al., 1989) . Although not as well differentiated as other thyroid cell models such as rat FRTL5 cells, Nthy-ori are human cells with well-described growth characteristics and are PPFP negative (data not shown).
We examined the growth of Nthy-ori cells following transient transfection with a CMV promoter-driven PPFP expression cassette, confirming successful PPFP expression by RT-PCR (data not shown). PPFPtransfected cells displayed significantly accelerated proliferation (Po0.0004) when compared with pcDNA3.1 control transfectants (Figure 1a) .
We next assessed cell cycle transit and apoptosis rates in the transient PPFP-and control-transfected cells. Compared to control cells, the proportion of PPFP transfectants in G2 þ S/M at 72 h was increased by 8.4% (Po0.002), whereas that of resting-phase cells (G0 þ G1) was decreased by 7.8% (Po0.006) (Figure 1b) , demonstrating a significant increase in cell cycle transit in the PPFP transfectants. Apoptosis rates in the PPFP transfectants were decreased by 42% at 48 h, and by 66% at 72 h post transfection compared with control cells (Po0.0005) (Figure 1c ). Consequently, increased proliferation of PPFP-transfected cells is attributable to a combination of modestly accelerated cell-cycle progression and a large decrease in apoptosis rate.
To establish whether stable PPFP expression would lead to a sustained growth advantage, we created cell lines with stable expression of PPFP or the pcDNA3.1 control vector and assessed their growth. We confirmed PPFP overexpression in the permanent PPFP transfectants by immunofluorescence using a PPARg antibody (Figure 2a ). Permanent cell lines expressing PPFP demonstrated a significant growth advantage over control or pcDNA3.1-transfected Nthy-ori cells, confirming that the growth advantage represents a stable, heritable phenotype (Figure 2b ).
PPFP expression causes loss of anchorage-dependent growth and contact inhibition
We assessed whether PPFP-expressing cell lines exhibit anchorage-independent growth using a soft-agar cloning assay. All of the stable cell lines derived from PPFP transfectants and none of the control cell lines expressed PPFP mRNA, before being placed in soft agar (RT-PCR data not shown). In eight PPFP cell lines, there was a mean of 8.6 colonies/plate (range 1-21), while only a single soft-agar colony was formed in one of four control plates, (Figure 3a ; Po0.03), consistent with the low-level anchorage-independent growth potential of native Nthy-ori 3-1cells (Burns et al., 1989; Lemoine et al., 1989) . These data demonstrate that PPFP expression significantly abrogates the anchorage dependence of growth in Nthy-ori cells.
We next evaluated PPFP's ability to transform NIH 3T3 cells. This focus-forming assay is a well-established test of oncogene action, and provides a measure of loss of contact inhibition (Allen et al., 2000; Meriane et al., 2002) . H-ras and the thyroid-specific RET/PTC-1 oncogene served as positive controls in these experiments. Transfection of NIH 3T3 cells with PPFP significantly increased the number of colonies in this assay, when compared with pcDNA3.1 vector transfectants ( Figure 3b ). Indeed, PPFP was nearly as potent as RET/PTC-1 in transforming these cells, suggesting that it acts to suppress contact inhibition.
PPARg overexpression alone is not sufficient to confer PPFP's oncogenic actions
We next examined whether PPARg overexpression alone could lead to increased cell growth, by transfecting Nthy-ori cells with a full-length PPARg expression construct, PPFP expression vector, or pcDNA3.1 control vector. A full-length PPARg expression construct, a PPFP expression construct, or the pcDNA3.1 control vector were transfected into Nthy-ori cells, which were shown by Western blot to express endogenous PPARg (Figure 4a ). There was no difference in cellgrowth rate, cell-cycle distribution and apoptosis rate between PPARg and control transfectants, whereas PPFP increased cell-growth ( Figure 4b ) and cell-cycle progression and reduced apoptosis (data not shown). This excludes a major role of PPARg overexpression alone in PPFP-mediated malignant transformation, and agrees well with previous data showing that PPARg inhibits thyroid cell growth (Martelli et al., 2002; Ohta et al., 2002; Satoh et al., 2002) .
A PPARg antagonist mimics the growth-promoting effects of PPFP
Since PPFP exerts a dominant-negative effect on wildtype PPARg in the PPARg-null U2OS osteosarcoma cells in vitro , PPFP may also inhibit endogenous PPARg inNthy-ori cells. Indeed, cotransfection of PPFP and PPARg in Nthy-ori cells revealed a robust inhibition of PPARg transactivation ( Figure 4c ). To extend these findings, we treated pcDNA-and PPFP-transfected Nthy-ori 3-1 cells with the potent and irreversible PPARg inhibitor GW9662, which has been shown to abrogate PPARg-mediated effects on gene expression (Huang et al., 1999) . This resulted in a dose-dependent increase in cell growth compared with control transfectants (Figure 4d ). At 10 mM, the maximal growth-promoting effect of GW9662 equalled the PPFP-induced growth effect in Nthy-ori cells. 
Discussion
Our data provide the first experimental evidence for an oncogenic effect of the PAX8/PPARg fusion oncoprotein. In our model systems, PPFP appeared to act on several key aspects of tumorigenesis by increasing cell cycle transition, reducing apoptosis and inducing loss of both anchorage dependence and contact inhibition. Each of these effects is a recognized facet of malignant transformation (Hanahan and Weinberg, 2000; Knudson, 2001) , and thus our data support the concept that PPFP interferes with multiple growth-regulatory pathways. While we do not yet know whether PPFP alone is sufficient to induce malignant transformation in vivo, it is likely a key contributor to the pathogenesis of FTC harboring the PAX8-PPARg rearrangement. Furthermore, the concordant effects of PPFP on both immortalized normal human thyrocytes (Nthy-ori 3-1) and fetal mouse fibroblasts (NIH 3T3 cells) suggest that at least some PPFP effects are mediated through common cell-regulatory pathways.
Further details of PPFP's oncogenic mechanism remain to be elucidated. The PPFP fusion protein contains much of PAX8, including its DNA-binding domain but not its critical C-terminal activation domain (Poleev et al., 1995) . PPFP also contains a near fulllength PPARg sequence, encoding DNA-binding, ligand-binding, and RXR dimerization and transactivation domains. Thus, the oncogenic activities of PPFP In this study, we focused on the relationship between PPFP and PPARg, since the latter is a ligand-activated transcription factor with a recognized role in cell differentiation and inhibition of cell growth. Liganded PPARg induces apoptosis and reduces cell growth in a variety of cell lines that express the PPARg receptor (Cimini et al., 2000; Takashima et al., 2001; Satoh et al., 2002) . PPARg appears to be dysregulated in a number of cell lines derived from human tumors, and PPARg ligands generally exhibit antiproliferative effects on such cells (Kubota et al., 1998; Mueller et al., 1998 Mueller et al., , 2000 Sarraf et al., 1998) , suggesting that overexpression of PPARg itself is unlikely to be oncogenic in thyroid cells. This was confirmed in our PPARg overexpression experiments, demonstrating that PPARg had no effect on Nthy-ori cell growth (Figure 4b) . Furthermore, the apparent downregulation of PPARg expression has been demonstrated in some FTC, providing circumstantial evidence for an antiproliferative role by wild-type PPARg in a subset of these tumors (Sarraf et al., 1999; Aldred et al., 2003; French et al., 2003) . Our in vitro evidence showed that PPFP exerts a dominant-negative 
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J Gregory Powell et al effect on PPARg-induced gene transcription in Nthy-ori cells, and this mechanism is further supported by our data demonstrating that the potent PPARg antagonist GW9662 (Huang et al., 1999) recapitulates the PPFPinduced growth increase in Nthy-ori cells (Figure 4d ). Although these data do not prove that PPFP works exclusively through wild-type PPARg inhibition, this appears to be major facet of PPFP action. In particular, the lack of further growth acceleration in PPFP transfectants treated with GW9662 suggests that the PPFP fusion oncoprotein may achieve maximal inhibition of wild-type PPARg. PPARg inhibition by PPFP could involve competition for DNA-binding sites, competition by a nonfunctional transcription factor for the PPARg ligand, or interference with the required heterodimerization between PPARg and RXR (IJpenberg et al., 1997), all of which require further investigation.
While PPARg inhibition appears to be linked to Nthy-ori cell growth, we do not know whether PPFP has additional oncogenic actions. Loss of PAX8 function or unique fusion-gene-specific properties could create other activities. PAX8 is essential for the development and maintenance of differentiated thyroid follicular cell function, and even heterozygous inactivation of PAX8 function can cause human thyroid agenesis (Vilain et al., 2001) . It is possible that PPFP might inhibit PAX8 function through a mechanism analogous to its inhibition of PPARg, and thereby alter the expression of genes required for follicular cell differentiation, including expression of the sodiumiodide transporter, thyroglobulin genes (Ohno et al., 1999; Espinoza et al., 2001) , and thyrocyte growth control.
Since 30-60% of FTC exhibit PPFP expression Marques et al., 2002; Nikiforova et al., 2002; French et al., 2003) , it is likely that both PPFPdependent and PPFP-independent pathways exist in follicular carcinoma formation. One such pathway may involve mutations of the RAS gene family, which have been implicated in both FTC and PTC and rarely occur together with PPFP rearrangements in FTC (Nikiforova et al., 2003) . RAS mutations are detected in a wide spectrum of follicular tumors, including benign follicular adenomas, in apparent contrast to PPFP. Activated RAS is known to cause thyrocyte proliferation, but only partial transformation, with ultimate self-limited cell expansion and senescence in primary cells Jones et al., 2000) . Similarly, in transgenic animals, activated RAS leads to benign thyroid tumors rather than carcinomas (Santelli et al., 1993) . Thus, RAS mutations may require additional transforming oncogenic events to form cancers, which may facilitate progression from adenoma to carcinoma. One interesting hypothesis is that an intact PPARg system in follicular cells with RAS-signaling alterations leads to PTC, a tumor type that may show less frequent PPARg downregulation (Aldred et al., 2003) , whereas PPARg downregulation with RAS pathway alterations may lead to PPFP-negative FTC. PPFP-independent pathways could also involve inactivation of PPARg by other mechanisms such as mutation, deletion or epigenetic alterations. Whatever the predominant mechanism of FTC formation in PPFP-negative tumors, our data argue that expression of PPFP is a key biologic event in the development of a significant proportion of FTC, and that this represents a major oncogenic mechanism in human thyroid cancer.
Materials and methods

Cell lines
We used SV40 large-T-antigen immortalized normal human differentiated thyroid cells, Nthy-ori 3-1 (European Collection of Cell Cultures, Wiltshire, UK), and NIH 3T3 cells (Dr Raul Urrutia, Mayo Clinic, Rochester, MN, USA). Nthy-ori cells were grown in RPMI 1640 Medium (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (BioWhittaker, Walkersville, MD, USA) and 6% penicillin-streptomycin-glutamine (Invitrogen) in 5% CO 2 at 371C. NIH 3T3 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) with 2 mM L-glutamine supplement plus 10% FBS, and incubated in 5% CO 2 at 371C. NIH 3T3 cells were maintained subconfluent to avoid spontaneous transformation.
Vectors
We cloned green fluorescent protein cDNA, PPFP fusion gene cDNA (TGK), full-length PPARg cDNA (Dr Ron Evans, Salk Institute, LaJolla, CA, USA), RET/PTC-1 thyroid oncogene cDNA (Dr James A. Fagin, University of Cincinnati, Cincinnati, OH, USA), and the H-Ras oncogene cDNA (Dr Raul Urrutia, Mayo Clinic, Rochester, MN, USA) into the mammalian expression vector pcDNA3.1 (Invitrogen), and confirmed the insert sequences by direct automated dye terminator sequencing (Applied Biosystems, Foster City, CA, USA).
Cell transfection
Transfection protocols were optimized using GFP expression vectors to achieve transfection efficiencies of 480%. For transient Nthy-ori transfection experiments, cells were grown to less than 80% confluence, trypsinized and plated at a density of 1.6 Â 10 5 cells/well in six-well plates (Costar, Corning Incorporated, Corning, NY, USA) for cell-proliferation assessment, and at a density of 6.0 Â 10 5 cells/plate in 10 cm Falcon plates (Becton Dickinson, Franklin Lakes, NJ, USA) for cell-cycle and apoptosis measurements. At 24 h after plating, we transfected the cells with 2 mg (cell-proliferation assays) or 8 mg (cell cycle and apoptosis measurements) of pcDNA3.1 control vector, PPFP-containing pcDNA3.1, or PPARg containing pcDNA3.1 (each in triplicate), using FuGENE 6 (Roche Diagnostics, Indianapolis, IN, USA). Stable Nthy-ori transfectants were created by subculturing cells in geneticin (Invitrogen)-enriched culture medium following control plasmid or PPFP plasmid transfection, as described above. Between 4 and 5 Â 10 5 of NIH 3T3 cells per 100 mm plate were seeded on the day before transfection. Cells were then transfected with 8 mg of PPFP-, RET/PTC-1-, H-Ras-, or control pcDNA3.1 vector, using FuGENE 6 (Roche Diagnostics). The transfection media was removed, the cells were rinsed with PBS twice, and incubated overnight in DMEM with 10% FBS at 371C in 5% CO 2 .
PPARg transactivation assay
Nthy-ori cells plated in six-well plates (Costar) were grown overnight and transfected with 3 : 1 Fugene to DNA . The expression cassettes included pCR3.1-PPFP or pCR3.1-PPARg (wild-type), aP2-Luc (firefly luciferase) containing the PPRE , and renilla luciferase as a control (Promega, Madison, WI, USA). Salmon sperm DNA was used for normalization. Expression of PPFP and PPARg was documented by Western blotting. Transfections proceeded for 72 h in medium containing 10% dextran/ charcoal-stripped fetal calf serum (Hyclone, Logan, UT, USA). The medium was supplemented with 1 mM Troglitazone (Biomol, Plymouth Meeting, PA, USA) during the last 24 h. Luciferase measurements were performed using a dualluciferase assay system (Promega).
Cell treatment with PPARg inhibitor
Nthy-ori cells were plated and transfected with pcDNA3.1 control plasmids or PPFP expression plasmids, as described above. We added GW9662 (Sigma-Aldrich, St Louis, MO, USA) at 1 and 10 mM final concentrations, and control cells treated with vehicle only. The culture medium was changed at 48 h and the inhibitor was replenished. Cell numbers were counted as described below.
Cell proliferation
For transient transfection experiments, we counted cell numbers at 6 (some experiments), 12 (some experiments), 24, 48, and 72 h following transfection, using a Coulter Counter (Coulter Channelyzer 256, Coulter Electronics, Hialeah, FL, USA). Prior to counting, cells were trypsinized with 0.5 ml of trypsin, followed by addition of 0.5 ml of RPMI with 10% fetal bovine serum to each plate. We added 0.5 ml of this mixture to 19.5 ml of isoton II (Beckman Coulter, Miami, FL, USA) and counted the samples. Stable Nthy-ori transfectants were plated at 2 Â 10 5 cells and counted 24, 48, 72, and 96 h later, using the same methodology.
Cell cycle and apoptosis
We harvested cells by trypsinization, as described above, at 24, 48, and 72 h after transfection. A FACScan flow cytometer (Becton Dickinson) was used for cell cycle and apoptosis assessment, using CELLQUEST analysis software (Becton Dickinson). For cell cycle assessment, we fixed cells with 95% ethanol, treated them with RNAse A (Roche Diagnostics), and stained them with propidium iodide (Molecular Probes, Eugene, OR, USA), before submitting them to flow cytometry (Hiddinga and Eberhardt, 1999) . Apoptosis staining and analysis were performed with 0.5 mg of annexin-V-biotin conjugate (Trevigen, Inc., Gaithersburg, MD, USA), 0.5 mg streptavidin-phycoerythrin (Molecular Probes), and 0.5 mg 7-aminoactinomycin-D (Molecular Probes) per 100 ml aliquoted sample, followed by flow cytometry (Hiddinga and Eberhardt, 1999) .
Soft agar colony assay
We soft-agar plated the Nthy-ori permanent control transfectants five times and the Nthy-ori PPFP cell lines in triplicate. Noble agar (DIFCO, Becton Dickinson, Sparks, MD, USA) was diluted using RPMI with 10% FBS medium to concentrations of 0.35, 0.45, and 0.5% noble agar in medium. A volume of 4 ml of 0.5% agar was added to each 60 mm plate and allowed to solidify at room temperature. In all, 5000 cells from a single geneticin-resistant clone were added to 4 ml of 0.45% medium and then added to a previously solidified 60 mm plate with 0.5% agar for control cell lines and for each PPFP cell line. A small portion of the cell/agar mixture was added to a 60 mm plate with media only for each sample, to assess cell survival during the agar-mixing process. After incubation for 24 h at 371C, 3 ml of 0.35% agar was added to the top of the plate. The agar was kept moist with a few drops of media every 4-5 days. We counted all colonies composed of 50 or more cells after 21-31 days using a Nikon Phase Contrast-2 microscope (Endfield, CT) at Â 40 magnification.
NIH 3T3 colony assay
Following transfection, NIH 3T3 cells were cultured for 12-15 days on 100 mm 2 plates. At the end of this period, we fixed the cells with 10% methanol and 10% acetic acid at room temperature for 10 min. The fixed cells were then stained with 0.04% crystal violet (Sigma) in 10% ethanol and all dark colonies over 0.3 cm in diameter were counted.
RT-PCR
We used RT-PCR followed by DNA sequencing to confirm the presence of PPFP expression in transient and permanent PPFP transfectants. PPARg expression in all transfectants was confirmed by the same method. We isolated RNA by TRIZOL (Invitrogen) extraction, according to the manufacturer's instructions, and reverse transcribed 1 mg of each RNA sample using MMLV reverse-transcriptase and an oligo-dT 17 primer (Mayo Clinic Molecular Biology Core Laboratory). The cDNAs were PCR-amplified using a sense primer derived from PAX8 exon 9 (5 0 -CATTACGGAGAGATCCACGG-3 0 ), and an antisense primer derived from PPARg exon 1 (5 0 -GCTCAACAGCACCCTGGA-3 0 ) for detection of PPFP, and with a sense primer derived from exon 1 of PPARg (5 0 -TTGACTTCTCCAGCATTTCTAC-3 0 ), and an antisense primer derived from exon 2 of PPARg (5 0 -CTTTATCTCCA-CAGACACGAC-3 0 ) for detection of PPARg. Direct sequencing of PCR products was accomplished by the automated fluorescent dye-terminator method (Applied Biosystems, Foster City, CA, USA), using the primers listed above.
Western blotting
Nthy-ori cells were grown to near confluence and harvested as described above. Cell lysis, protein extraction, SDS-polyacrylamide gel electrophoresis, and blotting were carried out as described (Jiang et al., 2001) . The Western blot was probed with a mouse monoclonal PPARg primary antibody (E-8, Santa Cruz Biotechnology, Santa Cruz, CA, USA), washed with PBS and incubated with horseradish-peroxidase-conjugated rabbit anti-mouse secondary antibody (Pierce Biotechnology, Rockford, IL, USA), followed by addition of SuperSignal s substrate (Pierce) and autoradiography (Jiang et al., 2001) .
Immunofluorescence
Cells were grown on Nunc (Nalge Nunc International, Naperville, IL, USA) four-well glass slides with media and conditions as described above. At 24 h, they were fixed with methanol and probed with E-8 PPARg mouse monoclonal antibody (Santa Cruz Biotechnology), washed with PBS, probed with a fluorescein-conjugated rabbit anti-mouse secondary antibody (Pierce) and imaged with a Fluoview
Statistical analysis
Continuous data between groups were analysed with twotailed t-tests after data transformation, if necessary, to ensure normality. Time-series data were analysed by ANOVA for repeated measures, with post hoc significance testing using the Bonferroni-Dunn test. Categorical data were compared between groups by the w 2 test or Fisher exact tests with appropriate degrees of freedom.
